|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 94 No. 11 (December 1), 1999:
pp. 3717-3721
Cellular Vascular Endothelial Growth Factor Is a Predictor of
Outcome in Patients With Acute Myeloid Leukemia
Alvaro Aguayo,
Elihu Estey,
Hagop Kantarjian,
Taghi Mansouri,
Cristi Gidel,
Michael Keating,
Francis Giles,
Zeev Estrov,
Bart Barlogie, and
Maher Albitar
From the Departments of Leukemia and Laboratory Medicine, the
University of Texas MD Anderson Cancer Center, Houston, TX; and the
University of Arkansas for Medical Sciences, Little Rock, AR.
Vascular endothelial growth factor (VEGF) is a potent mitogen for
vascular endothelial cells. It has been associated with angiogenesis,
growth, dissemination, metastasis, and poor outcome in solid tumors. To
assess cellular VEGF levels and their prognostic significance in newly
diagnosed acute myeloid leukemia (AML), we used a radioimmunoassay
(RIA) to quantify VEGF levels in stored samples obtained before
treatment from 99 patients with newly diagnosed AML treated at the MD
Anderson Cancer Center from 1996 to 1998. Outcome in the 99 patients
was representative of that observed in all patients seen at this
institution with this diagnosis during these years, but the 99 patients
had higher white blood cell (WBC) and blast counts than the other
patients. Results of the RIA were confirmed by Western blot. There was
a relationship between increasing VEGF levels and shorter survival
(P = .01), as well as shorter disease-free survival, both
from start of treatment and from complete response (CR) date. In
contrast, there was no relationship between VEGF level and WBC or blast
count, or between VEGF level and such established prognostic factors as
age, cytogenetics, performance status, or presence of an antecedent
hematologic disorder, and multivariate analysis indicated that VEGF was
still prognostic for the above outcomes after accounting for these
factors, as well as treatment. Our results suggest that at least in AML
patients with higher WBC and blast counts, cellular VEGF level is an
independent predictor of outcome.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Letter in Blood Online:
-
Angiogenesis in acute myeloid leukemia
- Francesco Di Raimondo, Giuseppe A. Palumbo, Maria Pia Azzaro, Rosario Giustolisi;, Teresa Padró, Wolfgang E. Berdel, Thomas Büchner, and Rolf M. Mesters
Blood 2000 96: 3656-3659.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
N. Rahimi, T. E. Golde, and R. D. Meyer
Identification of Ligand-Induced Proteolytic Cleavage and Ectodomain Shedding of VEGFR-1/FLT1 in Leukemic Cancer Cells
Cancer Res.,
March 15, 2009;
69(6):
2607 - 2614.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Kumpers, C. Koenecke, H. Hecker, J. Hellpap, R. Horn, W. Verhagen, S. Buchholz, B. Hertenstein, J. Krauter, M. Eder, et al.
Angiopoietin-2 predicts disease-free survival after allogeneic stem cell transplantation in patients with high-risk myeloid malignancies
Blood,
September 1, 2008;
112(5):
2139 - 2148.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Lowenberg
Acute Myeloid Leukemia: The Challenge of Capturing Disease Variety
Hematology,
January 1, 2008;
2008(1):
1 - 11.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Meshinchi and R. J. Arceci
Prognostic Factors and Risk-Based Therapy in Pediatric Acute Myeloid Leukemia
Oncologist,
March 1, 2007;
12(3):
341 - 355.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. A. Avramis, E. H. Panosyan, F. Dorey, J. S. Holcenberg, and V. I. Avramis
Correlation between High Vascular Endothelial Growth Factor-A Serum Levels and Treatment Outcome in Patients with Standard-Risk Acute Lymphoblastic Leukemia: A Report from Children's Oncology Group Study CCG-1962
Clin. Cancer Res.,
December 1, 2006;
12(23):
6978 - 6984.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Liu, M. Guo, Y.-B. Xu, D. Li, Z.-N. Zhou, Y.-L. Wu, Z. Chen, S. C. Kogan, and G.-Q. Chen
Induction of tumor arrest and differentiation with prolonged survival by intermittent hypoxia in a mouse model of acute myeloid leukemia
Blood,
January 15, 2006;
107(2):
698 - 707.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Faderl, K.-A. Do, M. M. Johnson, M. Keating, S. O'Brien, I. Jilani, A. Ferrajoli, F. Ravandi-Kashani, C. Aguilar, A. Dey, et al.
Angiogenic factors may have a different prognostic role in adult acute lymphoblastic leukemia
Blood,
December 15, 2005;
106(13):
4303 - 4307.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. O. Iversen and H. Wiig
Tumor Necrosis Factor {alpha} and Adiponectin in Bone Marrow Interstitial Fluid from Patients with Acute Myeloid Leukemia Inhibit Normal Hematopoiesis
Clin. Cancer Res.,
October 1, 2005;
11(19):
6793 - 6799.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. W.L. Yee, A. Hagey, S. Verstovsek, J. Cortes, G. Garcia-Manero, S. M. O'Brien, S. Faderl, D. Thomas, W. Wierda, S. Kornblau, et al.
Phase 1 Study of ABT-751, a Novel Microtubule Inhibitor, in Patients with Refractory Hematologic Malignancies
Clin. Cancer Res.,
September 15, 2005;
11(18):
6615 - 6624.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Loges, G. Heil, M. Bruweleit, V. Schoder, M. Butzal, U. Fischer, U. M. Gehling, G. Schuch, D. K. Hossfeld, and W. Fiedler
Analysis of Concerted Expression of Angiogenic Growth Factors in Acute Myeloid Leukemia: Expression of Angiopoietin-2 Represents an Independent Prognostic Factor for Overall Survival
J. Clin. Oncol.,
February 20, 2005;
23(6):
1109 - 1117.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Wadleigh, D. J. DeAngelo, J. D. Griffin, and R. M. Stone
After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignancies
Blood,
January 1, 2005;
105(1):
22 - 30.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. K. Lee, N. D. Bone, A. K. Strege, T. D. Shanafelt, D. F. Jelinek, and N. E. Kay
VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG), in B-cell chronic lymphocytic leukemia
Blood,
August 1, 2004;
104(3):
788 - 794.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Garcia de la Torre, I. Buley, J. A. H. Wass, D. G. Jackson, and H. E. Turner
Angiogenesis and Lymphangiogenesis in Parathyroid Proliferative Lesions
J. Clin. Endocrinol. Metab.,
June 1, 2004;
89(6):
2890 - 2896.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. E. Karp, I. Gojo, R. Pili, C. D. Gocke, J. Greer, C. Guo, D. Qian, L. Morris, M. Tidwell, H. Chen, et al.
Targeting Vascular Endothelial Growth Factor for Relapsed and Refractory Adult Acute Myelogenous Leukemias: Therapy with Sequential 1-{beta}-D-Arabinofuranosylcytosine, Mitoxantrone, and Bevacizumab
Clin. Cancer Res.,
June 1, 2004;
10(11):
3577 - 3585.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. X. Chen
Expanding the Clinical Development of Bevacizumab
Oncologist,
June 1, 2004;
9(suppl_1):
27 - 35.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Bieker, T. Padro, J. Kramer, M. Steins, T. Kessler, S. Retzlaff, F. Herrera, J. Kienast, W. E. Berdel, and R. M. Mesters
Overexpression of Basic Fibroblast Growth Factor and Autocrine Stimulation in Acute Myeloid Leukemia
Cancer Res.,
November 1, 2003;
63(21):
7241 - 7246.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Meshinchi, D. L. Stirewalt, T. A. Alonzo, Q. Zhang, D. A. Sweetser, W. G. Woods, I. D. Bernstein, R. J. Arceci, and J. P. Radich
Activating mutations of RTK/ras signal transduction pathway in pediatric acute myeloid leukemia
Blood,
August 15, 2003;
102(4):
1474 - 1479.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. J. Giles, A. T. Stopeck, L. R. Silverman, J. E. Lancet, M. A. Cooper, A. L. Hannah, J. M. Cherrington, A.-M. O'Farrell, H. A. Yuen, S. G. Louie, et al.
SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes
Blood,
August 1, 2003;
102(3):
795 - 801.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A.-M. O'Farrell, T. J. Abrams, H. A. Yuen, T. J. Ngai, S. G. Louie, K. W. H. Yee, L. M. Wong, W. Hong, L. B. Lee, A. Town, et al.
SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo
Blood,
May 1, 2003;
101(9):
3597 - 3605.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Benekli, M. R. Baer, H. Baumann, and M. Wetzler
Signal transducer and activator of transcription proteins in leukemias
Blood,
April 15, 2003;
101(8):
2940 - 2954.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-M. Liu, F. Lawrence, M. Kovacevic, J. Bignon, E. Papadimitriou, J.-Y. Lallemand, P. Katsoris, P. Potier, Y. Fromes, and J. Wdzieczak-Bakala
The tetrapeptide AcSDKP, an inhibitor of primitive hematopoietic cell proliferation, induces angiogenesis in vitro and in vivo
Blood,
April 15, 2003;
101(8):
3014 - 3020.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. E. Karp, D. D. Ross, W. Yang, M. L. Tidwell, Y. Wei, J. Greer, D. L. Mann, T. Nakanishi, J. J. Wright, and A. D. Colevas
Timed Sequential Therapy of Acute Leukemia with Flavopiridol: In Vitro Model for a Phase I Clinical Trial
Clin. Cancer Res.,
January 1, 2003;
9(1):
307 - 315.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Schuch, M. Machluf, G. Bartsch Jr, M. Nomi, H. Richard, A. Atala, and S. Soker
In vivo administration of vascular endothelial growth factor (VEGF) and its antagonist, soluble neuropilin-1, predicts a role of VEGF in the progression of acute myeloid leukemia in vivo
Blood,
December 15, 2002;
100(13):
4622 - 4628.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. O. Iversen, C. A. Drevon, and J. E. Reseland
Prevention of leptin binding to its receptor suppresses rat leukemic cell growth by inhibiting angiogenesis
Blood,
December 1, 2002;
100(12):
4123 - 4128.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. S. J. M. de Bont, V. Fidler, T. Meeuwsen, F. Scherpen, K. Hahlen, and W. A. Kamps
Vascular Endothelial Growth Factor Secretion Is an Independent Prognostic Factor for Relapse-free Survival in Pediatric Acute Myeloid Leukemia Patients
Clin. Cancer Res.,
September 1, 2002;
8(9):
2856 - 2861.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. M. Rimsza, K. P. Ahrens, J. K. Massey, K. M. Pastos, M. G. Mainwaring, and R. C. Braylan
AML, angiogenesis, and prognostic variables
Blood,
July 30, 2002;
100(4):
1517 - 1518.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Dias, S. V. Shmelkov, G. Lam, and S. Rafii
VEGF165 promotes survival of leukemic cells by Hsp90-mediated induction of Bcl-2 expression and apoptosis inhibition
Blood,
April 1, 2002;
99(7):
2532 - 2540.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Verstovsek, H. Kantarjian, T. Manshouri, J. Cortes, F. J. Giles, A. Rogers, and M. Albitar
Prognostic significance of cellular vascular endothelial growth factor expression in chronic phase chronic myeloid leukemia
Blood,
March 15, 2002;
99(6):
2265 - 2267.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. B. Steins, T. Padro, R. Bieker, S. Ruiz, M. Kropff, J. Kienast, T. Kessler, T. Buechner, W. E. Berdel, and R. M. Mesters
Efficacy and safety of thalidomide in patients with acute myeloid leukemia
Blood,
February 1, 2002;
99(3):
834 - 839.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. F. List, K. J. Kopecky, C. L. Willman, D. R. Head, D. L. Persons, M. L. Slovak, R. Dorr, C. Karanes, H. E. Hynes, J. H. Doroshow, et al.
Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study
Blood,
December 1, 2001;
98(12):
3212 - 3220.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Koomagi, F. Zintl, A. Sauerbrey, and M. Volm
Vascular Endothelial Growth Factor in Newly Diagnosed and Recurrent Childhood Acute Lymphoblastic Leukemia as Measured by Real-Time Quantitative Polymerase Chain Reaction
Clin. Cancer Res.,
November 1, 2001;
7(11):
3381 - 3384.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. F. List
Vascular Endothelial Growth Factor Signaling Pathway as an Emerging Target in Hematologic Malignancies
Oncologist,
October 1, 2001;
6(2008):
24 - 31.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. J. Giles
The Vascular Endothelial Growth Factor (VEGF) Signaling Pathway: A Therapeutic Target in Patients with Hematologic Malignancies
Oncologist,
October 1, 2001;
6(2008):
32 - 39.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Masood, J. Cai, T. Zheng, D. L. Smith, D. R. Hinton, and P. S. Gill
Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors
Blood,
September 15, 2001;
98(6):
1904 - 1913.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Dias, K. Hattori, B. Heissig, Z. Zhu, Y. Wu, L. Witte, D. J. Hicklin, M. Tateno, P. Bohlen, M. A. S. Moore, et al.
Inhibition of both paracrine and autocrine VEGF/ VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias
PNAS,
September 11, 2001;
98(19):
10857 - 10862.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. M. Mesters, T. Padro, R. Bieker, M. Steins, M. Kreuter, M. Goner, S. Kelsey, P. Scigalla, W. Fiedler, T. Buchner, et al.
Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia
Blood,
July 1, 2001;
98(1):
241 - 243.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Hattori, S. Dias, B. Heissig, N. R. Hackett, D. Lyden, M. Tateno, D. J. Hicklin, Z. Zhu, L. Witte, R. G. Crystal, et al.
Vascular Endothelial Growth Factor and Angiopoietin-1 Stimulate Postnatal Hematopoiesis by Recruitment of Vasculogenic and Hematopoietic Stem Cells
J. Exp. Med.,
May 7, 2001;
193(9):
1005 - 1014.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Wellmann, T. Taube, K. Paal, H. Graf v. Einsiedel, W. Geilen, G. Seifert, C. Eckert, G. Henze, and K. Seeger
Specific Reverse Transcription-PCR Quantification of Vascular Endothelial Growth Factor (VEGF) Splice Variants by LightCycler Technology
Clin. Chem.,
April 1, 2001;
47(4):
654 - 660.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Ferrajoli, T. Manshouri, Z. Estrov, M. J. Keating, S. O’Brien, S. Lerner, M. Beran, H. M. Kantarjian, E. J. Freireich, and M. Albitar
High Levels of Vascular Endothelial Growth Factor Receptor-2 Correlate with Shortened Survival in Chronic Lymphocytic Leukemia
Clin. Cancer Res.,
April 1, 2001;
7(4):
795 - 799.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
B. D. Smolich, H. A. Yuen, K. A. West, F. J. Giles, M. Albitar, and J. M. Cherrington
The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts
Blood,
March 1, 2001;
97(5):
1413 - 1421.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. T. Bellamy, L. Richter, D. Sirjani, C. Roxas, B. Glinsmann-Gibson, Y. Frutiger, T. M. Grogan, and A. F. List
Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes
Blood,
March 1, 2001;
97(5):
1427 - 1434.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. T.-P. Poon, S.-T. Fan, and J. Wong
Clinical Implications of Circulating Angiogenic Factors in Cancer Patients
J. Clin. Oncol.,
February 15, 2001;
19(4):
1207 - 1225.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. J. Klasa, A. F. List, and B. D. Cheson
Rational Approaches to Design of Therapeutics Targeting Molecular Markers
Hematology,
January 1, 2001;
2001(1):
443 - 462.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Mesa, C. A. Hanson, S. V. Rajkumar, G. Schroeder, and A. Tefferi
Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia
Blood,
November 15, 2000;
96(10):
3374 - 3380.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Di Raimondo, G. A. Palumbo, M. P. Azzaro, R. Giustolisi;, T. Padro, W. E. Berdel, T. Buchner, and R. M. Mesters
Angiogenesis in acute myeloid leukemia
Blood,
November 15, 2000;
96(10):
3656 - 3659.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Aguayo, H. Kantarjian, T. Manshouri, C. Gidel, E. Estey, D. Thomas, C. Koller, Z. Estrov, S. O'Brien, M. Keating, et al.
Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes
Blood,
September 15, 2000;
96(6):
2240 - 2245.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Aguayo, S. O'Brien, M. Keating, T. Manshouri, C. Gidel, B. Barlogie, M. Beran, C. Koller, H. Kantarjian, and M. Albitar
Clinical relevance of intracellular vascular endothelial growth factor levels in B-cell chronic lymphocytic leukemia
Blood,
July 15, 2000;
96(2):
768 - 770.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
